Spotlight – Few signs of gout pipeline flaring up
Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.
2023’s biggest launches: the story so far
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
Sobi strikes again
CTI Biopharma sees an unlikely end to its 32-year rollercoaster existence.
Catalysts ahead for the smaller players
Calliditas heads for confirmatory data in IgA nephropathy, while Viking and 89Bio are set for key readouts in Nash.
Ash 2022 preview – Novartis has Apellis in its sights
Iptacopan looks as good as Empaveli in PNH, with the added bonus of being oral.
ISTH 2022 – Sanofi faces more fitusiran doubts
An investigator asks whether the haemophilia project, which has already been linked with toxicity concerns, should be given to elderly patients.
Sanofi scores a win with long-acting haemophilia project
Interim results on bleeds look impressive, but more data are needed to gauge efanesoctocog alfa's chances against Roche's Hemlibra.
Key big pharma catalysts to kick off 2022
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.